Skip to content

Anesthesia management of bronchoscope

evaluate the application two monitoring anesthesia management of remifentanil and sufentanil in the diagnosis and treatment of severe tracheal stenosis by bronchoscopy: a randomized controlled trial

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100043380
Enrollment
Unknown
Registered
2021-02-12
Start date
2021-02-15
Completion date
Unknown
Last updated
2021-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

anesthesia for bronchoscopy

Interventions

R group:Remifentanil TCI
S group:Sufentanil TCI

Sponsors

Shanghai Pulmonary Hospital, Tongji University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients with severe tracheal stenosis Myer-cotton gradation 2-4; 2. Undergoing fiberoptic bronchoscopy; 3. Aged 18-65 years; 4. ASA I-III; 5. BMI18.5~30 kg/m2.

Exclusion criteria

Exclusion criteria: 1) Patients with chronic pain who have used analgesics, psychotropic drugs (including opioids, NSAIDs, sedatives, and antidepressants), alcohol abusers for a long time. 2) Liver and kidney functions (ALT, AST, BUN, Cr) are abnormally increased before surgery, which is more than 1.5 times the normal value. 3) History of abnormal surgical anesthesia recovery. 4) In the past or at present, patients had hypertension which could not be controlled by drugs, or systolic blood pressure >= 170 mmHg or diastolic blood pressure >= 100 mmHg during the screening period. 5) Suffer from esophageal reflux disease. 6) Sedatives, antiemetics, and antipruritic drugs were used 24 hours before the operation. 7) Expected to be difficult intubation. 8) History of opioid allergy. 9) Take monoamine oxidase inhibitors or antidepressants within 15 days. 10) Shock patients. 11) Patients with acute exacerbation of chronic obstructive pulmonary disease (COPD). 12) Pregnant or parturient. 13)Patients who do not sign informed consent.

Design outcomes

Primary

MeasureTime frame
The incidence of hypoxemia;;

Secondary

MeasureTime frame
Cough score;the alteration of HR and BP;OAA/S score and Ramsay score;Fully awake time;The degree and incidence of nausea and vomiting;Questionnaire on satisfaction of subjects and anesthesiologists;

Countries

China

Contacts

Public ContactLiu Jianming

Shanghai Pulmonary Hospital, Tongji University

liujianming@126.com+86 13761323891

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 11, 2026